Jin Yong Lee, Director of the Health Insurance Review and Assessment Research Institute, expressed his personal view that the government should raise the prices of high-priced drugs that confirm improved outcomes with real-world data (RWD).

Currently, the Health Insurance Review and Assessment Service conducts performance analysis for some high-priced drugs with RWD to manage NHI reimbursement expenditures. However, the purpose of the system is mostly in retrieving the reimbursed expenditures, and there is no mechanism established to allow drug price increases for better-performing drugs.

However, Director Lee strongly expressed the need for a mechanism to increase the drug pric